Vaccine partnering terms and agreements

311 views

Published on

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

Published in: Health & Medicine, Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
311
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Vaccine partnering terms and agreements

  1. 1. Vaccine Partnering Terms and Agreements The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccines The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vac cine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including d etails of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  2. 2. The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and deal making since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, develop ment and commercialization of vaccine technologies and products. Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide. Vaccine Partnering Terms and Agreements includes: Trends in vaccine dealmaking in the biopharma industry since 2007 Analysis of vaccine deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life vaccine deals Access to over 1,500 vaccine deal documents The leading vaccine deals by value since 2007 Most active vaccine dealmakers since 2007 The leading vaccine partnering resources In Vaccine Partnering Terms and Agreements, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 vaccine deals. Analyzing actual contract agreements allows assessment of the following: What are the precise vaccine rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization?
  3. 3.  Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Vaccine Partnering Terms and Agreements provides the reader with the following key benefits: In-depth understanding of vaccine and adjuvant deal trends since 2007 Access to headline, upfront, milestone and royalty data Analysis of the structure of vaccine agreements with numerous real life case studies Comprehensive access to over 1500 actual vaccine contracts entered into by the world’s biopharma companies Detailed access to actual vaccine contracts enter into by the leading fifty bigpharma companies Insight into the terms included in a vaccine agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Buy Your Copy of Report http://www.reportsnreports.com/reports/134835- vaccine-partnering-terms-and-agreements.html Report Details: Published: June 2012 No. of Pages: 882 Single User License Price: US $ 2695 Corporate User License Price: US $ 13475 Table of Contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in vaccine dealmaking 2.1. Introduction 2.2. Companion vaccine over the years 2.3. Bigpharma vaccine dealmaking activity
  4. 4. 2.4. Bigpharma not active in vaccines2.5. Vaccine partnering by deal type2.6. Vaccine partnering by disease type2.7 Average deal terms for vaccine2.7.1 Vaccine headline values2.7.2 Vaccine upfront payments2.7.3 Vaccine milestone payments2.7.4 Vaccine royalty ratesChapter 3 – Leading vaccine deals3.1. Introduction3.2. Top vaccine deals by value3.3. Top vaccine deals involving bigpharmaChapter 4 – Bigpharma vaccine deals4.1. Introduction4.2. How to use bigpharma vaccine partnering deals4.3. Bigpharma vaccine partnering company profilesAbbottActavisActelionAllerganAmgenAspen PharmacareAstellasAstraZenecaBaxter InternationalBayerBiogen IdecBoehringer IngelheimBristol-Myers SquibbCelgeneCSLDaiichi SankyoDainippon SumitomoEisaiEli LillyEndo PharmaceuticalsForest LaboratoriesGaldermaGilead SciencesGlaxoSmithKline
  5. 5. GrifolsHospiraJohnson & JohnsonKyowa Hakko KirinLundbeckMenariniMerck & CoMerck KGaAMitsubishi TanabeMylanNovartisNovo NordiskOtsukaPfizerPurdueRocheSanofiServierShionogiTakedaTevaUCBValeantWarner ChilcottWatsonChapter 5 – Vaccine dealmaking directory5.1. Introduction5.2. Company A-Z5.3. By stage of developmentDiscoveryPre-clinicalPhase IPhase IIPhase IIIRegistrationMarketed5.4. By deal typeAsset purchaseAssignmentBigpharma outlicensing
  6. 6. Co-developmentCollaborative R&DCo-marketContract serviceCo-promotionCRADACross-licensingDevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingLitigationManufacturingMarketingMaterial transferOptionPromotionResearchRoyalty financingSettlementSpin outSub-licenseSupplyTechnology transferTerminationWarranty5.5. By therapy areaAnestheticsCardiovascularCentral nervous systemDentalDermatologyGastrointestinalGenitourinaryHematologyHospital careImmunologyInfectives
  7. 7. InflammatoryMetabolicMusculoskeletalOncologyOphthalmicsPsychiatryPublic healthRespiratorySexual health5.6. By associated technology typeAdjuvantChapter 6 – Partnering resource center6.1. Online partnering6.2. Partnering events6.3. Further reading on dealmakingAppendicesAppendix 1 – Deal type definitionsAppendix 2 – Example vaccine partnering agreementAbout Wildwood VenturesList of FiguresFigure 1: Vaccine partnering since 2007Figure 2: Bigpharma – top 50 – vaccine deals 2007 to 2012Figure 3: Bigpharma vaccine deal frequency – 2007 to 2012Figure 4: Inactive bigpharma in vaccine partnering 2007-2012Figure 5: Vaccine partnering by deal type since 2007Figure 6: Vaccine partnering by disease type since 2007Figure 7: Vaccine partnering by infectives target since 2007Figure 8: Vaccine partnering by oncology target since 2007Figure 9: Vaccine deals with a headline value – by stage of developmentFigure 10: Vaccine deal headline value distribution, US$million – discovery stageFigure 11: Vaccine deal headline value distribution, US$million – preclinic stageFigure 12: Vaccine deal headline value distribution, US$million – phase I stageFigure 13: Vaccine deal headline value distribution, US$million – phase II stageFigure 14: Vaccine deal headline value distribution, US$million – phase III stageFigure 15: Vaccine deal headline value distribution, US$million – marketed stageFigure 16: Vaccine deal headline value – median value by stage of developmentFigure 17: Vaccine deals with upfront payment values – by stage of developmentFigure 18: Vaccine deal upfront payment distribution, US$million – discovery stage deals
  8. 8. Figure 19: Vaccine deal upfront payment distribution, US$million – prelinic stage dealsFigure 20: Vaccine deal upfront payment distribution, US$million – phase I stage dealsFigure 21: Vaccine deal upfront payment distribution, US$million – phase II stage dealsFigure 22: Vaccine deal upfront payment distribution, US$million – phase III stage dealsFigure 23: Vaccine deal upfront payment distribution, US$million – marketed stage dealsFigure 24: Vaccine deal upfront value – median value by stage of developmentFigure 25: Vaccine deals with milestone payment – by stage of developmentFigure 26: Vaccine deal milestone payment distribution, US$million – discovery stage dealsFigure 27: Vaccine deal milestone payment distribution, US$million – prelinic stage dealsFigure 28: Vaccine deal milestone payment distribution, US$million – phase I stage dealsFigure 29: Vaccine deal milestone payment distribution, US$million – phase II stage dealsFigure 30: Vaccine deal milestone payment distribution, US$million – phase III stage dealsFigure 31: Vaccine deal milestone payment distribution, US$million – marketed stage dealsFigure 32: Vaccine deal milestone payments – median value by stage of developmentFigure 33: Vaccine deals with royalty ratesFigure 34: Top vaccine deals by value since 2007Figure 35: Top vaccine deals signed by bigpharma value since 2007Figure 36: Recent deals (Jan 2007 to May 2012) - By therapy area (AnestheticsFigure 37: Recent deals (Jan 2007 to May 2012) - By therapy area (CardiovascularFigure 38: Recent deals (Jan 2007 to May 2012) - By therapy area (Central Nervous System)Figure 39: Recent deals (Jan 2007 to May 2012) - By therapy area (Dental)Figure 40: Recent deals (Jan 2007 to May 2012) - By therapy area (Dermatology)Figure 41: Recent deals (Jan 2007 to May 2012) - By therapy area (Gastrointestinal)Figure 42: Recent deals (Jan 2007 to May 2012) - By therapy area (Genitourinary)Figure 43: Recent deals (Jan 2007 to May 2012) - By therapy area (Hematology)Figure 44: Recent deals (Jan 2007 to May 2012) - By therapy area (Hospital care)Figure 45: Recent deals (Jan 2007 to May 2012) - By therapy area (Immunology)Figure 46: Recent deals (Jan 2007 to May 2012) - By therapy area (Infectives)Figure 47: Recent deals (Jan 2007 to May 2012) - By therapy area (Inflammatory)Figure 48: Recent deals (Jan 2007 to May 2012) - By therapy area (Metabolic)Figure 49: Recent deals (Jan 2007 to May 2012) - By therapy area (Musculoskeletal)Figure 50: Recent deals (Jan 2007 to May 2012) - By therapy area (Oncology)Figure 51: Recent deals (Jan 2007 to May 2012) - By therapy area (Ophthalmics)Figure 52: Recent deals (Jan 2007 to May 2012) - By therapy area (Psychiatry)Figure 53: Recent deals (Jan 2007 to May 2012) - By therapy area (Public health)Figure 54: Recent deals (Jan 2007 to May 2012) - By therapy area (Respiratory)Figure 55: Recent deals (Jan 2007 to May 2012) - By therapy area (Sexual health)Figure 56: Online partnering resourcesFigure 57: Forthcoming partnering eventsFigure 58: Deal type definitionsFigure 59: Vaccine partnering agreement between Novavax and LG Life Sciences, March 2011
  9. 9. Browse more Research Reports @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact Us:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441Email: sales@reportsandreports.comConnect With Us:

×